Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xiaoshen Wang
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Eye & ENT Hospital of Fudan University
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Eye & ENT Hospital of Fudan University
ORCID:
0000-0003-1446-5485
Observed ORCID:
0000-0003-1446-5485
OpenAlex ID:
A5018490486
Identification of Significant Secreted or Membrane-Located Proteins in Laryngeal Squamous Cell Carcinoma
2022
·
Li Yan
, Chunyan Hu
, et al.
·
Journal of Immunology Research
·
12
PDF
HPV associated oropharyngeal cancer in eastern China over the last 7 years: is the incidence in chinese truly exceptionally low?
2025
·
Ruichen Li
, Ji Li
, et al.
·
BMC Public Health
·
4
PDF
Number of positive lymph nodes and lymph node ratio predict recurrence and survival in hypopharyngeal cancer based on SEER database and validation of real-world data
2024
·
Ruichen Li
, Xiaoshen Wang
·
European Archives of Oto-Rhino-Laryngology
·
3
Survival Outcomes and Late Toxicity of Postoperative Radiotherapy in Patients With Adenoid Cystic Carcinoma of the External Auditory Canal
2025
·
Li Wang
, Xinmao Song
, et al.
·
Cancer Medicine
·
2
PDF
Superior Regional Control and Laryngeal Function Preservation With Radiotherapy Versus Partial Laryngectomy: A Propensity Score‐Matched Analysis of 562 Early Glottic Cancer Patients
2025
·
Shaoqiu Zhang
, Ruichen Li
, et al.
·
Head & Neck
·
2
PDF
The value of elective neck irradiation in management of esthesioneuroblastoma: a retrospective study based on propensity score matching
2024
·
Yang Zhao
, Li Yan
, et al.
·
Radiation Oncology
·
2
PDF
p16 status or response to induction chemotherapy, which predicts survival outcomes in Chinese oropharyngeal cancer treated with definitive radiotherapy?
2024
·
Ruichen Li
, Yang Zhao
, et al.
·
Radiotherapy and Oncology
·
2
Prognostic impact and risk factors of level IV/V lymph nodes metastasis in laryngeal squamous cell carcinoma
2025
·
Ruichen Li
, Siyuan Ma
, et al.
·
Oral Oncology
·
1
First-line tislelizumab, pegaspargase, and gemcitabine with consolidative radiotherapy for early-stage extranodal NK/T-cell lymphoma: a single-arm, phase II trial
2026
·
Tian Wang
, Xiang Liu
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Phase III randomized trial of tislelizumab plus gemcitabine/capecitabine (GX) versus tislelizumab plus gemcitabine/cisplatin (GP) as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma: A prospective multicenter study (PROGRESS).
2026
·
Dongmei Ji
, Yanan Yang
, et al.
·
Journal of Clinical Oncology
PDF
A phase II clinical study of PD-1 inhibitor tislelizumab combined with chemotherapy for unresectable recurrent locally advanced nasopharyngeal carcinoma (RETICULA-NPC trial).
2026
·
Xiaoshen Wang
, Ye Zhang
, et al.
·
Journal of Clinical Oncology
Penpulimab (AK105) combined with cetuximab as first-line treatment in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II clinical trial.
2026
·
Shu Tian
, Qin Zhao
, et al.
·
Journal of Clinical Oncology
Multimodality Multimask and Multitask Auto-Segmentation Network for Organs-at-Risk in Head and Neck Radiation Therapy
2026
·
Xiaochen Ni
, Tianci Tang
, et al.
·
Advances in Radiation Oncology
PDF
Show more works
View as search
Works count:
13
Citation count:
28
H-index:
3
I10-index:
1
Year
Topic
Type